Preferred Label : Agammaglobulinemia, X-linked;
Symbol : XLA;
CISMeF acronym : AGMX1; IMD1; XLA;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Bruton-type agammaglobulinemia; Agammaglobulinemia, X-linked, type 1; Immunodeficiency 1; AGMX1; IMD1;
Included titles and symbols : Hypogammaglobulinemia, X-linked;
Description : X-linked agammaglobulinemia is an immunodeficiency characterized by failure to produce
mature B lymphocytes and associated with a failure of Ig heavy chain rearrangement.
The defect in this disorder resides in BTK, also known as BPK or ATK, a key regulator
in B-cell development (Rawlings and Witte, 1994). The X-linked form accounts for approximately
85 to 90% of cases of the disorder. Also see 300310. The remaining 15% of cases constitute
a heterogeneous group of autosomal disorders (Lopez Granados et al., 2002; Ferrari
et al., 2007). See agammaglobulinemia-1 (AGM1; 601495) for a discussion of genetic
heterogeneity of the autosomal forms of agammaglobulinemia.;
Inheritance : X-linked recessive;
Molecular basis : Caused by mutation in the Bruton agammaglobulinemia tyrosine kinase gene (BTK, 300300.0001);
Neoplasia : Increased incidence of rectosigmoid cancer;
Laboratory abnormalities : Absent or severely reduced levels of serum immunoglobulins;
Prefixed ID : #300755;
Origin ID : 300755;
UMLS CUI : C0221026;
- Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- DO Cross reference
- Genes related to phenotype
- HPO term(s)
- ORDO concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)